Ismahane Belhabib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ismahane Belhabib has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Annemilai Tijeras-Raballand
OncoMega, France
1 shared publication - Christine Jean
UCSD Moores Cancer Center, La Jolla, CA
1 shared publication - Cindy Neuzillet
GI Oncology, Department of Medical Oncology, Institut Curie, Versailles Saint-Quentin University, Saint-Cloud, France
1 shared publication - Corinne Bousquet
University Toulouse III Paul Sabatier
1 shared publication - Milena Muzzolini
Department of General and Digestive Surgery, Hôpital Saint Antoine, Assistance Publique – Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France
1 shared publication - Renato Micelli Lupinacci
Department of Digestive and Oncologic Surgery, Ambroise Paré Hospital, Boulogne-Billancourt, France
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 38, e382823
Pancreatic cancer orthotopic graft in a murine model
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with increasing incidence. Even if progress have been made, the five-year overall survival remains lower than 10%. There is a desperate need in therapeutic improvements. In the last two decades, new in-vitro models have been developed and improved, including tridimensional-culture spheroids and organoids. However, animal studies remain mandatory in the upscaling before clinical studies. Orthotopic and syngeneic grafting is a robust model to test a drug efficiency in a tumor and its microenvironment.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 38, e382823
Open AccessPancreatic cancer orthotopic graft in a murine model
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with increasing incidence. Even if progress have been made, the five-year overall survival remains lower than 10%. There is a desperate need in therapeutic improvements. In the last two decades, new in-vitro models have been developed and improved, including tridimensional-culture spheroids and organoids. However, animal studies remain mandatory in the upscaling before clinical studies. Orthotopic and syngeneic grafting is a robust model to test a drug efficiency in a tumor and its microenvironment.